Gene Therapy: Lyfgenia Voucher Denial Puts Sickle Cell Treatment At Risk, Bluebird Bio Says

 
• By Sue Sutter
  
Bluebird bio's cash is running out, putting access to Lyfgenia at risk. (Shutterstock)

More from Cell & Gene Therapies

More from Advanced Technologies